A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation

A Validated LC–MS/MS Assay for the Simultaneous Quantification of the FDA-Approved Anticancer Mixture (Encorafenib and Binimetinib): Metabolic Stability Estimation

The concurrent use of oral encorafenib (Braftovi, ENF) and binimetinib (Mektovi, BNB) is a combination anticancer therapy approved by the United States Food and Drug Administration (USFDA) for patients with BRAFV600E/V600K mutations suffering from metastatic or unresectable melanoma. Metabolism is c...

Full description

Bibliographic Details
Main Authors: Mohamed W. Attwa, Hany W. Darwish, Nasser S. Al-Shakliah, Adnan A. Kadi
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Molecules
Subjects:
binimetinib
encorafenib
LC–MS/MS
metabolic stability assessment
P450 module
Online Access:https://www.mdpi.com/1420-3049/26/9/2717

Similar Items

Similar Items